Multicultural Community Dementia Screening

多元文化社区痴呆症筛查

基本信息

批准号：
10578575
负责人：
James E Galvin
金额：
$ 25.39万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10578575
关键词：
Address Administrative Supplement Alzheimer disease detection Alzheimer disease screening Alzheimer&apos s disease related dementia Amyloid Amyloid deposition Anatomy Angiography Animal Model Atrophic Biological Markers Brain Brain imaging Clinical Clinical Trials Cognitive Cohort Studies Communities Computer software Cultural Diversity Curcumin Data Dementia Detection Discrimination Disease Early Diagnosis Enrollment Eye Funding Fundus Future Genetic Gold Image Impaired cognition Impairment Individual Institutes Intake Intervention Knowledge Lasers Link Magnetic Resonance Imaging Methodology Methods Nerve Degeneration Neuronal Injury Neurons Ophthalmoscopy Optical Coherence Tomography Oral Parents Participant Pathology Patients Pharmaceutical Preparations Phenotype Physiological Plasma Population Positron-Emission Tomography Prevalence Preventive Research Retina Scanning Spinal Puncture Study Subject Testing Therapeutic Time Validation Work amyloid imaging clinical care clinical diagnosis cognitive performance cohort cost effective diagnostic biomarker gray matter image processing improved in vivo in vivo imaging magnetic resonance imaging biomarker mild cognitive impairment novel pre-clinical public health relevance resilience retinal imaging screening symptomatology tau Proteins vascular injury

项目摘要

ABSTRACT Community detection of Mild cognitive impairment (MCI) and early Alzheimer’s disease and related dementias (ADRD) may be limited due to the lack of screening tests characterizing the earliest signs of impairment and correspondence to biomarkers as defined by the amyloid-tau-neuronal injury/neurodegeneration (ATN) framework. Accumulating evidence suggests that neuronal injury and neurodegeneration begins decades before clinically evident cognitive decline. Thus, by the time ADRD is clinically diagnosed, irreversible neuronal damage has already occurred. This has the potential of lessening the therapeutic benefits of disease modifying medications. In R01AG071514, we are examining novel ways to overcome major challenges to improve the detection of MCI and early AD by emphasizing deep phenotyping to enhance the research value of data and biospecimens contributed by individual participants and cross validate screening efforts linking prevalence data to brain biomarkers, leveraging the ATN research framework to anchor this work. However most current ATN biomarkers are expansive, invasive and not readily accessible for clinical care. To address this critical need, we aim to develop non-invasive, easily acquired biomarkers conducive for the early detection of ADRD. The retina and brain share similar anatomic and physiologic features, but, unlike the brain, the retina is easily accessible for imaging. The retina and brain share similar anatomic and physiologic features, but, unlike the brain, the retina is easily accessible for imaging. Recent studies showed that amyloid deposition occurs not only in the brain but also in the retina, greater in patients with AD compared to normal healthy controls. For this administrative supplement, we teamed with Drs. Jianhua Wang and Hong Jiang, experts in ophthalmic imaging of the Advanced Ophthalmic Imaging lab at the Bascom Palmer Eye Institute. Confocal scanning laser ophthalmoscopy (cSLO) will be used along with OCT/OCTA to image the retina before and after oral curcumin intake. This proposed work takes advantage of well-characterized and deeply phenotyped cohort from our funded R01 AG071514. We propose 3 SPECIFIC AIMS: (1) Develop and validate retinal amyloid imaging; (2) Determine relationship of retinal amyloid imaging to brain amyloid imaging; and (3) test whether baseline retinal amyloid imaging can predict transition. At the conclusion of our study, we will collect sufficient preliminary data for future R01 proposal and the cost-effective and noninvasive method for in vivo imaging of amyloid deposition in the retina will be fully developed to be used for screening and clinical trials.

抽象的社区发现轻度认知障碍（MCI）和早期阿尔茨海默氏病和相关痴呆症（ADRD）由于缺乏筛查测试而被限制，这表征了最早的损害迹象和与淀粉样蛋白 - tau-神经元损伤/神经变性（ATN）定义的生物标志物的对应关系框架。积累的证据表明，神经元损伤和神经退行性几十年前开始临床上证据认知能力下降。在临床上诊断出ADRD时，不可逆的神经元损害已经发生了。这有可能降低疾病修饰的治疗益处药物。在R01AG071514中，我们正在研究克服主要挑战以改善主要挑战的新方法通过强调深层表型来检测MCI和早期AD，以增强数据的研究价值和由个别参与者贡献的生物测量和跨验证筛查工作将流行数据联系起来为了大脑生物标志物，利用ATN研究框架来锚定这项工作。但是最新的ATN 生物标志物是额外的，侵入性的，并且不容易获得临床护理。为了满足这一关键需求，我们旨在开发非侵入性的，易于获得的生物标志物导电剂以早期检测ADRD。视网膜大脑具有相似的解剖和生理特征，但是，与大脑不同，视网膜很容易获得用于成像。视网膜和大脑具有相似的解剖和生理特征，但与大脑不同，视网膜很容易进入成像。最近的研究表明，淀粉样沉积不仅发生在大脑中但在视网膜中，与正常健康对照相比，AD患者的较大。对于此行政补充，我们与Drs合作。 Jianhua Wang和Hong Jiang，高级眼光成像专家 Bascom Palmer Eye Institute的眼科成像实验室。共聚焦扫描激光眼镜检查（CSLO）将与OCT/OCTA一起使用，以在口服姜黄素摄入之前和之后对视网膜进行成像。这提出了工作利用了我们资助的R01 AG071514的特征良好和深层表型的队列。我们提案3特定目的：（1）开发和验证残留的淀粉样蛋白成像；（2）确定关系视网膜淀粉样蛋白成像至脑淀粉样蛋白成像；（3）测试基线视网膜淀粉样蛋白成像是否可以预测过渡。在我们的研究结束时，我们将收集足够的初步数据提案以及视网膜中淀粉样蛋白沉积体内成像的成本效益和无创方法将完全开发用于筛查和临床试验。